A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy

Obstet Gynecol. 2014 Aug;124(2 Pt 2 Suppl 1):454-456. doi: 10.1097/AOG.0000000000000389.

Abstract

Background: Cisplatin is considered safe to use during the second and third trimesters of pregnancy in patients with cancer.

Case: A 34-year-old pregnant woman was diagnosed with cervical cancer. She received five weekly dosages of cisplatin and paclitaxel, starting at 26 5/7 weeks of gestation. An elective cesarean delivery was performed at 34 4/7 weeks of gestation. After birth, the neonate was diagnosed with severe bilateral perceptive hearing loss.

Conclusion: Cisplatin during the second and third trimesters of pregnancy may lead to fetal ototoxicity.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Squamous Cell / drug therapy*
  • Cisplatin / adverse effects*
  • Female
  • Hearing Loss, Bilateral / chemically induced*
  • Hearing Loss, Bilateral / congenital
  • Humans
  • Infant, Newborn
  • Male
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Severity of Illness Index
  • Uterine Cervical Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Cisplatin